Literature DB >> 6849764

Pharmacokinetics of promethazine and its sulphoxide metabolite after intravenous and oral administration to man.

G Taylor, J B Houston, J Shaffer, G Mawer.   

Abstract

Blood concentrations of promethazine and promethazine sulphoxide have been measured following oral and intravenous administration of promethazine to seven healthy male volunteers. Promethazine disposition is characterised by a large volume of distribution (1970 1) and a high blood clearance (1.141 min-1). Less than 1% of the dose is excreted unchanged in the urine, therefore total body clearance is essentially metabolic clearance. In accord with this high clearance the oral availability of promethazine is only 25%. The absorption of promethazine from the gastrointestinal tract exceeds 80% in most subjects. Minimal metabolism by the gastrointestinal mucosa is implicated. Promethazine sulphoxide pharmacokinetics are consistent with a pronounced first pass effect. Although the area under the curve for this metabolite is not route dependent, there is a marked alteration in the shape of the metabolite curve when oral and intravenous data are compared. Evidence is presented to support the hypothesis that S-oxidation of promethazine is predominantly an hepatic event. The conclusions of previous investigators with regard to the role of the gut mucosa in S-oxidation of phenothiazines is critically assessed.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6849764      PMCID: PMC1427776          DOI: 10.1111/j.1365-2125.1983.tb01501.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  14 in total

1.  Pharmacokinetics of methotrimeprazine after single and multiple doses.

Authors:  S G Dahl
Journal:  Clin Pharmacol Ther       Date:  1976-04       Impact factor: 6.875

Review 2.  Plasma level monitoring of antipsychotic drugs.

Authors:  T B Cooper
Journal:  Clin Pharmacokinet       Date:  1978 Jan-Feb       Impact factor: 6.447

3.  Albumin binding and hydrophobic character of promazine and chlorpromazine metabolites.

Authors:  J Kriegelstein; F Lier; J Michaelis
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1972       Impact factor: 3.000

4.  Simultaneous determination of promethazine and two of its circulating metabolites by high-performance liquid chromatography.

Authors:  G Taylor; J B Houston
Journal:  J Chromatogr       Date:  1982-06-11

5.  Noncompartmental determination of the steady-state volume of distribution.

Authors:  L Z Benet; R L Galeazzi
Journal:  J Pharm Sci       Date:  1979-08       Impact factor: 3.534

6.  First-pass metabolism of imipramine in man.

Authors:  L F Gram; J Christiansen
Journal:  Clin Pharmacol Ther       Date:  1975-05       Impact factor: 6.875

7.  Clinical pharmacokinetic studies of perphenazine.

Authors:  C Eggert Hansen; T Rosted Christensen; J Elley; L Bolvig Hansen; P Kragh-Sorensen; N E Larsen; J Naestoft; E F Hvidberg
Journal:  Br J Clin Pharmacol       Date:  1976-10       Impact factor: 4.335

Review 8.  Monitoring plasma concentrations of neuroleptics.

Authors:  M Lader
Journal:  Pharmakopsychiatr Neuropsychopharmakol       Date:  1976-07

9.  Destruction of chlorpromazine during absorption in the rat in vivo and in vitro.

Authors:  S H Curry; A D'Mello; G P Mould
Journal:  Br J Pharmacol       Date:  1971-07       Impact factor: 8.739

10.  First pass hydroxylation of nortriptyline: concentrations of parent drug and major metabolites in plasma.

Authors:  G Alván; O Borga; M Lind; L Palmér; B Siwers
Journal:  Eur J Clin Pharmacol       Date:  1977-03-11       Impact factor: 2.953

View more
  13 in total

1.  The sulfoxidation of fluphenazine in schizophrenic patients maintained on fluphenazine decanoate.

Authors:  K K Midha; J W Hubbard; S R Marder; E M Hawes; T Van Putten; G McKay; P R May
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

2.  Drug metabolite concentration-time profiles: influence of route of drug administration.

Authors:  J B Houston; G Taylor
Journal:  Br J Clin Pharmacol       Date:  1984-04       Impact factor: 4.335

3.  Genetic aspects of the polymodally distributed sulphoxidation of S-carboxymethyl-L-cysteine in man.

Authors:  S C Mitchell; R H Waring; C S Haley; J R Idle; R L Smith
Journal:  Br J Clin Pharmacol       Date:  1984-10       Impact factor: 4.335

Review 4.  Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines).

Authors:  D M Paton; D R Webster
Journal:  Clin Pharmacokinet       Date:  1985 Nov-Dec       Impact factor: 6.447

Review 5.  Treatment of nausea and vomiting in terminally ill cancer patients.

Authors:  Paul A Glare; David Dunwoodie; Katherine Clark; Alicia Ward; Patsy Yates; Sharon Ryan; Janet R Hardy
Journal:  Drugs       Date:  2008       Impact factor: 9.546

6.  Oral premedication for the prevention of hypersensitivity reactions to paclitaxel.

Authors:  Jamal Zidan; O Hussein; A Abzah; S Tamam; Z Farraj; E Friedman
Journal:  Med Oncol       Date:  2008-03-25       Impact factor: 3.064

7.  A physiologically based pharmacokinetic model to predict the pharmacokinetics of highly protein-bound drugs and the impact of errors in plasma protein binding.

Authors:  Min Ye; Swati Nagar; Ken Korzekwa
Journal:  Biopharm Drug Dispos       Date:  2016-04       Impact factor: 1.627

Review 8.  Treating nausea and vomiting in palliative care: a review.

Authors:  Paul Glare; Jeanna Miller; Tanya Nikolova; Roma Tickoo
Journal:  Clin Interv Aging       Date:  2011-09-12       Impact factor: 4.458

9.  Use of Promethazine and Meperidine as Premedicants in Asthmatics before Initiation of Surgery: An Interim Report.

Authors:  Zahid Hussain Khan; Milad Minagar; Mohammad Dehghan-Tezerjani
Journal:  Adv J Emerg Med       Date:  2019-07-29

Review 10.  Antitussives and substance abuse.

Authors:  Jarrett M Burns; Edward W Boyer
Journal:  Subst Abuse Rehabil       Date:  2013-11-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.